Trospium / Xanomeline and Lopinavir: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Trospium / Xanomeline
Lopinavir
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Your medicine Cobenfy (which contains xanomeline) can briefly slow down an enzyme in your gut called CYP3A4. Lopinavir is broken down partly by that same enzyme. When they are taken together, a little more lopinavir may get absorbed, which could make its side effects (like nausea, diarrhea, or stomach upset) show up more often or feel stronger.
The good news is this is a theoretical concern, meaning it is based on how the drugs work rather than lots of real-world reports. Your care team can manage it easily by keeping an eye on how you feel. Please keep taking both as prescribed and let your pharmacist or doctor know if you notice anything new.
Mechanism: Xanomeline (in Cobenfy) transiently inhibits intestinal CYP3A4, not systemic CYP3A4. Lopinavir is a CYP3A4 substrate, so gut-level inhibition may increase its oral exposure (AUC/Cmax).
Direction: Increased lopinavir exposure, raising the frequency and/or severity of lopinavir-related adverse reactions (GI upset, etc.). Neither agent's effect here is prodrug-dependent.
- Severity: Moderate
- Onset: Unspecified
- Evidence: Theoretical
Management: Monitor for increased or more severe substrate-related adverse effects. Dose may be individualized by the care team if clinically warranted.
What happens
Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-related adverse reactions
Interaction Deep Dive
In the gut, xanomeline produces a transient, local inhibition of CYP3A4, though this effect does not extend systemically. When xanomeline is taken together with oral medications that are sensitive CYP3A4 substrates, the exposure to those oral substrates may rise. Such an increase can lead to greater frequency and/or severity of adverse reactions associated with these substrates. During concurrent administration, patients should be monitored for any rise in the frequency and/or severity of adverse reactions linked to oral drugs that are sensitive CYP3A4 substrates1.
Why it happens (mechanism)
Inhibition of CYP3A4-substrate metabolism by xanomeline
How to manage this interaction
Here is how a care team typically handles this:
- Keep taking both as prescribed unless your prescriber tells you otherwise.
- Your team may monitor you more closely for lopinavir side effects such as nausea, diarrhea, or stomach discomfort.
- If side effects become more frequent or stronger, your dose may be adjusted and individualized by your care team.
What to do: Tell your pharmacist or doctor if you notice new or worsening side effects. Because this concern is theoretical, watchful monitoring is usually all that is needed.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Trospium / Xanomeline and Lopinavir together?
Taking Cobenfy (xanomeline) with lopinavir may slightly raise lopinavir levels and its side effects, but this is a theoretical concern that your care team can manage by monitoring you and adjusting the dose if needed. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Trospium / Xanomeline and Lopinavir interaction?
It is rated moderate. Can be significant — usually manageable with monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Trospium / Xanomeline and Lopinavir interaction managed?
Here is how a care team typically handles this: Keep taking both as prescribed unless your prescriber tells you otherwise. Your team may monitor you more closely for lopinavir side effects such as nausea, diarrhea, or stomach discomfort. If side effects become more frequent or stronger, your dose may be adjusted and individualized by your care team. What to do: Tell your pharmacist or doctor if yo… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Trospium / Xanomeline or Lopinavir need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there anything you'd monitor while I'm on both?
References (1)
- Citation #1
Keep reading about Trospium / Xanomeline
Keep reading about Lopinavir
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist